Cargando…

Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment

The canine is the most important large animal model for testing novel hemophilia A(HA) treatment. It is often necessary to use canine factor VIII (cFIII) gene or protein for the evaluation of HA treatment in the canine model. However, the different biological properties between cFVIII and human FVII...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qizhao, Dong, Biao, Firrman, Jenni, Wu, Wenman, Roberts, Sean, Moore, Andrea Rossi, Liu, LinShu, Chin, Mario P.S., Diao, Yong, Kost, Joseph, Xiao, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936945/ https://www.ncbi.nlm.nih.gov/pubmed/27064790 http://dx.doi.org/10.1038/gt.2016.34

Ejemplares similares

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
por: Firrman, Jenni, et al.
Publicado: (2020)

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
por: Cao, Wenjing, et al.
Publicado: (2020)

Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors
por: Wang, Qizhao, et al.
Publicado: (2016)

In vitro and In vivo Model Systems for Hemophilia A Gene Therapy
por: Mao, Jianhua, et al.
Publicado: (2013)

A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors
por: Wang, Qizhao, et al.
Publicado: (2017)

A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota
por: Wang, Minqian, et al.
Publicado: (2019)

Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice
por: Song, Shuxian, et al.
Publicado: (2022)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII
por: Chen, Hainan, et al.
Publicado: (2019)

Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice
por: Lange, Amy M, et al.
Publicado: (2016)

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
por: Russick, Jules, et al.
Publicado: (2020)

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
por: Stem, Christopher, et al.
Publicado: (2021)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A
por: Hart, Daniel P., et al.
Publicado: (2019)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Analysis of the Ability of Capsaicin to Modulate the Human Gut Microbiota In Vitro
por: Mahalak, Karley K., et al.
Publicado: (2022)

A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A
por: Tatsumi, Kohei, et al.
Publicado: (2013)

Apigenin Impacts the Growth of the Gut Microbiota and Alters the Gene Expression of Enterococcus
por: Wang, Minqian, et al.
Publicado: (2017)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2016)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A
por: Rose, Melanie, et al.
Publicado: (2020)

Analysis of Temporal Changes in Growth and Gene Expression for Commensal Gut Microbes in Response to the Polyphenol Naringenin
por: Firrman, Jenni, et al.
Publicado: (2018)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
por: Han, Jeong Pil, et al.
Publicado: (2021)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nuuik81icbho1q0nghcrmeaag0